🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cliff Asness’s SGMT Holdings & Trades

First Buy
Q3 2026
Duration Held
1 Quarters
Largest Add
Q3 2026
+16,759 Shares
Current Position
16,759 Shares
$165,579 Value

Cliff Asness's SGMT Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 16,759 shares of Sagimet Biosciences Inc. (SGMT) worth $165,579, representing 0.00% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Cliff Asness has initiated a new position in SGMT, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's Sagimet Biosciences (SGMT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Sagimet Biosciences (SGMT) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +16,759 New Buy 16,759 $9.88

Cliff Asness's Sagimet Biosciences Investment FAQs

Cliff Asness first purchased Sagimet Biosciences Inc. (SGMT) in Q3 2026, acquiring 16,759 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held Sagimet Biosciences Inc. (SGMT) for 1 quarters since Q3 2026.

Cliff Asness's largest addition to Sagimet Biosciences Inc. (SGMT) was in Q3 2026, adding 16,759 shares worth $165,579.

According to the latest 13F filing for Q3 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 16,759 shares of Sagimet Biosciences Inc. (SGMT), valued at approximately $165,579.

As of the Q3 2026 filing, Sagimet Biosciences Inc. (SGMT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in Sagimet Biosciences Inc. (SGMT) was 16,759 shares, as reported at the end of Q3 2026.